logo
Share SHARE
FONT-SIZE Plus   Neg

BlueLinx Completes $40 Mln Rights Offering

BlueLinx Holdings Inc. (BXC) said Friday that it has completed its previously announced $40 million rights offering.

The company said previously that it would use the net proceeds of the rights offering of about $38.7 million to reduce the outstanding balance of its U.S. revolving credit facility.

Following the issuance of the newly subscribed shares, which is expected to occur on or about April 1, BlueLinx will have about 86.6 million total shares outstanding.

After giving effect to the offering, Cerberus ABP Investor LLC beneficially owns about 54.4% of BlueLinx' common stock.

Concurrent with the completion of the rights offering, BlueLinx's previously announced amendment and extension to its $400 million U.S. revolving credit facility became effective. As a result of the amendment and extension, the company's existing $400 million credit facility was increased by $22.5 million to $422.5 million and the maturity date was extended to April 15, 2016.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Packaged food producer ConAgra Brands Inc. reported Thursday higher net profit in its fourth quarter with margin strength. Net sales, meanwhile, declined from last year on weak volume. Looking ahead, for fiscal 2018, the company projects higher adjusted earnings and lower to flat sales. The company also reiterated its three-year fiscal 2020 financial algorithm. Best Buy announced Wednesday its plans to introduce Amazon Alexa and Google Home experiences to its 700 locations across the U.S. starting next month as part of its strategy of pushing smart home technology. A nationwide rollout will be complete by the end of the year. The electronics retailer will expand space at selected stores to better showcase how Amazon's Echo and Google Home interact.. So far this year, 23 novel drugs have already received FDA approval. Now let's take a look at the biotech stocks waiting to hear from the FDA in July.
comments powered by Disqus
Follow RTT